HeartFlow: Transforming the Diagnosis and Management of Coronary Artery Disease

Founded in 2007, HeartFlow is a medical technology company transforming the way cardiovascular disease is diagnosed and treated. With the company's HeartFlow Analysis, a non-invasive personalized cardiac test, physicians are able to make better care decisions for their patients with suspected coronary artery disease--the number one killer of men and women worldwide. HeartFlow is backed by decades of scientific research and development and leverages the latest advancements in technology to help set a new standard of care for diagnosing cardiovascular care worldwide.

Cleared for use in the United States, Canada, Europe and Japan and with offices in Redwood City, Austin, London and Japan, HeartFlow’s footprint is growing rapidly. HeartFlow has received more than $240 million dollars in funding in a recent Series E financing round, is pre-IPO and leverages the latest technology including deep learning and computational fluid dynamics.

There is truly no company in the world doing what HeartFlow is doing —combining decades of human ingenuity and advanced technology in a completely novel way. They are passionate about transforming the diagnosis and management of coronary artery disease and continue to innovate, pushing into new frontiers and forging incredible partnerships along the way.

Looking to Transform Diagnosis

While HeartFlow continues to trailblaze in the field of cardiology, the company is proud of its numerous accomplishments bringing them to where they are today, including more than 100,000 patients served, adoption at more than 400+ hospitals worldwide—including 80% of the Top 50 US Heart Hospitals—full coverage by Medicare and 96% of commercial lives in the United States, a robust body of clinical evidence, including more than 500 peer-reviewed publications, and an IP portfolio of more than 400 issued and allowed patents worldwide. HeartFlow is committed to continuing to transform the diagnosis and management of coronary artery disease and are grateful for the countless collaborations today and in the future to make this vision a reality worldwide.

The HeartFlow Analysis is a non-invasive diagnostic test that helps physicians identify the impact that blockages have on blood flow to the heart. By leveraging a standard CT, the latest advancements in AI, cloud computing and computational physiology, physicians get both anatomic and physiologic information in one test. This powerful combination of information allows physicians to clearly identify problem areas before entering the cath lab. The results are presented as a color-coded 3D model of a patient’s arteries and are available as a web application via desktop or mobile. This technology enabled the Cone Health team to better triage patients without the capital expense or investment often required when adopting new technology.

"We were early adopters of technology that enables more comprehensive evaluation of coronary artery disease by providing both anatomical and functional information and improves patients' outcomes," said Katarina Nelson, MD, CT Program Lead, Imaging Cardiologist.

Traditional diagnostic tests result in 20-30% false-negative rates1 and 55% false positive rates. In contrast, CT has a 98% negative predictive value allowing physicians to safely defer patients without disease, and when 30-90% disease is present and more information is needed, HeartFlow helps fill in the gaps by providing functional information. The HeartFlow Analysis is proven to have the highest diagnostic performance over other non-invasive tests with long-term outcomes out to five years. For the Cone Health team this translates to appropriate use of the cath lab for interventional procedures that are more predictable, well planned, coordinated and discussed with patients and the entire care team in advance of procedures. “This gave me a tool that I felt was more trustworthy and helped to get away from the high false positives we were getting with SPECT,” said Henry Smith, MD, Interventional Cardiologist.

Patient satisfaction has become an integral component of a value-based healthcare system, and adoption of innovative technologies can help support meeting these goals. With the HeartFlow Analysis, patients avoid the amount of time, money and anxiety that would have resulted from using other tests and instead benefit from an accurate diagnosis and a clearer understanding of their heart health. The Cone Health team now has more engaged patient-provider conversations which help put patients at the center of their care and build trust in the entire process. “By having a structured program with a dedicated team, you can create a better workflow and patient experience,” concluded Sheryl Booth, RT(R), MHA, Executive Director Heart & Vascular.

About the Leader

John H. Stevens, is the President, CEO and co-founder at HeartFlow. He has had a distinguished career as an entrepreneur and healthcare professional. Previously, he was the co-founder and CTO of Heartport and co-founder and executive chairman of Amp Resources.

"The HeartFlow Analysis is a non-invasive diagnostic test that helps physicians identify the impact that blockages have on blood flow to the heart."

"HeartFlow is backed by decades of scientific research and development and leverages the latest advancements in technology to help set a new standard of care for diagnosing cardiovascular care worldwide."

"HeartFlow is committed to continuing to transform the diagnosis and management of coronary artery disease and are grateful for the countless collaborations today and in the future to make this vision a reality worldwide."